Cargando…
HLA-DRB1*11 is a strong risk factor for acquired thrombotic thrombocytopenic purpura in children
Autores principales: | Joly, Bérangère S., Loiseau, Pascale, Darmon, Michael, Leblanc, Thierry, Chambost, Hervé, Fouyssac, Fanny, Guigonis, Vincent, Harambat, Jérôme, Stepanian, Alain, Coppo, Paul, Veyradier, Agnès |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Fondazione Ferrata Storti
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7556652/ https://www.ncbi.nlm.nih.gov/pubmed/33054098 http://dx.doi.org/10.3324/haematol.2019.241968 |
Ejemplares similares
-
Diagnosis and follow‐up of thrombotic thrombocytopenic purpura with an automated chemiluminescent ADAMTS13 activity immunoassay
por: Beranger, Nicolas, et al.
Publicado: (2020) -
The Specificities of Thrombotic Thrombocytopenic Purpura at Extreme Ages: A Narrative Review
por: Joseph, Adrien, et al.
Publicado: (2023) -
ADAMTS13 conformation is closed in non-immune acquired thrombotic thrombocytopenic purpura of unidentified pathophysiology
por: Joly, Bérangère S., et al.
Publicado: (2022) -
Immune-mediated thrombotic thrombocytopenic purpura following COVID-19 vaccination
por: Picod, Adrien, et al.
Publicado: (2022) -
More on the use of frontline caplacizumab in immune-mediated thrombotic thrombocytopenic purpura
por: Picod, Adrien, et al.
Publicado: (2022)